Skip to content

Extrahepatic Burden of Chronic Hepatitis C in Pakistan: A Cross-Sectional Analysis of Pain, Physical Dysfunction and Psychosocial Impairment Across Hepatic Dysfunction Stages

Distribution and Intensity of Referred Musculoskeletal Pain in Hepatitis C Patients: A Cross-Sectional Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12626000163303
Enrollment
172
Registered
2026-02-09
Start date
2026-01-15
Completion date
2026-05-08
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study aims to explore how people with Hepatitis C experience referred pain, meaning pain felt in body areas away from the liver, such as the shoulders, back, joints, or limbs. Although Hepatitis C mainly affects the liver, many patients report unusual or widespread pain that is not well understood. The purpose of this research is to identify where this pain occurs, how severe it is, and whether it is linked to the severity of liver disease. Participants will complete simple assessments, including a pain rating scale, a body map to show where pain is felt, and a liver function scoring system. We hypothesize that patients with more advanced Hepatitis C may show a greater intensity or wider distribution of referred pain. Understanding these pain patterns may help healthcare providers recognize Hepatitis C earlier, avoid misdiagnosis, and improve patient care.

Interventions

This study is purely observational and does not involve any therapeutic or behavioral intervention. The purpose is to observe and document referred pain patterns in patients diagnosed with Hepatitis C virus (HCV) infection. The condition being observed is Hepatitis C–related referred pain, including musculoskeletal, abdominal, and neuropathic pain presentations that are not anatomically localized to the liver. Pain characteristics, distribution, and severity will be recorded. Participants will u

This study is purely observational and does not involve any therapeutic or behavioral intervention. The purpose is to observe and document referred pain patterns in patients diagnosed with Hepatitis C virus (HCV) infection. The condition being observed is Hepatitis C–related referred pain, including musculoskeletal, abdominal, and neuropathic pain presentations that are not anatomically localized to the liver. Pain characteristics, distribution, and severity will be recorded. Participants will undergo: Child-Pugh Score assessment to grade liver disease severity. Numeric Pain Rating Scale (NPRS) to quantify pain intensity. Nordic Body Map (NBM) to document pain location and referred pain distribution patterns. A structured clinical interview documenting pain duration, nature, aggravating/relieving factors, and associated symptoms. Data collection will be carried out by a trained physiotherapist researcher with experience in clinical assessment and pain evaluation. Each participant will undergo a single observational assessment session lasting approximately 20–30 minutes. The overall study observation period will span for 4 months

This study is purely observational and does not involve any therapeutic or behavioral intervention. The purpose is to observe and document referred pain patterns in patients diagnosed with Hepatitis C virus (HCV) infection. The condition being observed is Hepatitis C–related referred pain, including musculoskeletal, abdominal and neuropathic pain presentations that are not anatomically localized to the liver. Pain characteristics, distribution, severity and associated psychosocial factors will

This study is purely observational and does not involve any therapeutic or behavioral intervention. The purpose is to observe and document referred pain patterns in patients diagnosed with Hepatitis C virus (HCV) infection. The condition being observed is Hepatitis C–related referred pain, including musculoskeletal, abdominal and neuropathic pain presentations that are not anatomically localized to the liver. Pain characteristics, distribution, severity and associated psychosocial factors will be documented. Participants will undergo: Child-Pugh Score assessment to grade liver disease severity. Numeric Pain Rating Scale (NPRS) to quantify pain intensity. Douleur Neuropathique 4 (DN4) questionnaire to screen for neuropathic pain features. Nordic Body Map (NBM) to document pain location and referred pain distribution patterns. Patient Health Questionnaire-9 (PHQ-9) for assessment of depressive symptoms. Generalized Anxiety Disorder-7 (GAD-7) for evaluation of anxiety symptoms. Fatigue Severity Scale (FSS) to assess fatigue severity. Pittsburgh Sleep Quality Index (PSQI) to evaluate sleep quality disturbances. Structured clinical interview documenting pain duration, nature, aggravating/relieving factors, treatment status, disease duration, comorbidities and associated symptoms. Physical examination including cervical, lumbar and right shoulder range of motion measured using a universal goniometer. Bilateral hand grip strength assessment using a hand dynamometer. Tender point examination to evaluate features suggestive of central sensitization. Recording of available serum ALT and AST values as markers of hepatic inflammation. Data collection will be carried out by a trained physiotherapist researcher experienced in clinical assessment and pain evaluation. Each participant will undergo a single observational assessment session lasting approximately 20–30 minutes. The overall study observation period will span 4 months.

Sponsors

Dr. Mehlaqa Waseem- Independent University Hospital, Faisalabad
Lead SponsorIndividual

Eligibility

Sex/Gender
All
Age
20 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

Adults aged 20–45 years. Confirmed diagnosis of Hepatitis C virus (HCV) infection by serological or molecular testing. Patients reporting musculoskeletal pain, abdominal discomfort, or other non-localized pain potentially related to HCV. Willingness and ability to provide written informed consent. Able to participate in a single face-to-face assessment session and complete the required questionnaires and pain mapping tools.

Exclusion criteria

Presence of other chronic liver diseases (e.g., Hepatitis B, alcoholic liver disease, autoimmune hepatitis). Pre-existing musculoskeletal disorders or neuropathic conditions unrelated to Hepatitis C. Current or recent use of long-term analgesic, anti-inflammatory, or immunomodulatory therapy that may affect pain perception. Pregnant or breastfeeding individuals. Patients unable to provide informed consent or complete the study assessments. Any serious comorbid conditions (e.g., advanced cardiac, renal, or neurological disorders) that could confound pain assessment.

Outcome results

None listed

Source: ANZCTR · Data processed: Sep 19, 2026